Pub Date : 2003-03-01DOI: 10.4048/JKBCS.2003.6.1.24
Ji Kun Kim, Soon Yong Park, Myung Kook Lim, C. W. Lee, H. Kim, K. Kwun, Soo Jung Lee
Purpose: A sentinel lymph node mapping with blue dye has been well accepted as a common procedure in breast cancer surgery. However, it is well known that blue dye absorbed into the circulation may interfere pulse oximetery reading. The aim of this study was to evaluate the change of pulse oximetery reading by isosulfan blue dye injection during sentinel lymph node mapping. Methods: Thirteen breast cancer patients with normal preoperative cardiopulmonary functions were studied. Four ml of isosulfan blue dye was injected subdermally when the patient became stable after induction of general anesthesia. The pulse oximetery was monitored continuously. Multiple arterial blood gas analyses (ABGA) were performed before dye injection and 10, 30, 40 minutes after dye injection. The results of oxygen saturturation by oximetery (SpO2) and the results of arterial oxygen tension (SaO2) and arterial oxygen saturation (SaO2) by ABGA were compared. Results: The value of both SaO2 and PaO2 measured by ABGA has not been altered by isosulfan dye injection. However SpO2 decreased by isosulfan dye injection. SpO2 decrease started 8.2±1.5 (2∼20) minutes after dye injection and returned to preinjection level by 85.7±5.6 (60∼126) minutes after injection. The lowest vaule of SpO2 was 95.6 ±1.2% (93∼97). Mean duration of SpO2 decrease was 77.5 ±6.2 (40∼117) minutes. The duration of SpO2 decrease was longer in the aged patients, but it was not statistically significant (p=0.3). There was no siginificant difference in duration of SpO2 decrease according to injection site, operation method, and body mass index (BMI). Conclusion: .Isosulfan dye injection using for sentinel lymph node mapping causes no change in true ABGA results but causes a mild reversible decrease in SpO2, It is important to look for other causes when SpO2 decrease is significant and persistent. (Journal of Korean Breast Cancer Society 2003;6:24-28)
{"title":"Decrease in Pulse Oximeter Readings Following Injection of Isosulfan Blue Dye","authors":"Ji Kun Kim, Soon Yong Park, Myung Kook Lim, C. W. Lee, H. Kim, K. Kwun, Soo Jung Lee","doi":"10.4048/JKBCS.2003.6.1.24","DOIUrl":"https://doi.org/10.4048/JKBCS.2003.6.1.24","url":null,"abstract":"Purpose: A sentinel lymph node mapping with blue dye has been well accepted as a common procedure in breast cancer surgery. However, it is well known that blue dye absorbed into the circulation may interfere pulse oximetery reading. The aim of this study was to evaluate the change of pulse oximetery reading by isosulfan blue dye injection during sentinel lymph node mapping. Methods: Thirteen breast cancer patients with normal preoperative cardiopulmonary functions were studied. Four ml of isosulfan blue dye was injected subdermally when the patient became stable after induction of general anesthesia. The pulse oximetery was monitored continuously. Multiple arterial blood gas analyses (ABGA) were performed before dye injection and 10, 30, 40 minutes after dye injection. The results of oxygen saturturation by oximetery (SpO2) and the results of arterial oxygen tension (SaO2) and arterial oxygen saturation (SaO2) by ABGA were compared. Results: The value of both SaO2 and PaO2 measured by ABGA has not been altered by isosulfan dye injection. However SpO2 decreased by isosulfan dye injection. SpO2 decrease started 8.2±1.5 (2∼20) minutes after dye injection and returned to preinjection level by 85.7±5.6 (60∼126) minutes after injection. The lowest vaule of SpO2 was 95.6 ±1.2% (93∼97). Mean duration of SpO2 decrease was 77.5 ±6.2 (40∼117) minutes. The duration of SpO2 decrease was longer in the aged patients, but it was not statistically significant (p=0.3). There was no siginificant difference in duration of SpO2 decrease according to injection site, operation method, and body mass index (BMI). Conclusion: .Isosulfan dye injection using for sentinel lymph node mapping causes no change in true ABGA results but causes a mild reversible decrease in SpO2, It is important to look for other causes when SpO2 decrease is significant and persistent. (Journal of Korean Breast Cancer Society 2003;6:24-28)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"247 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116208302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.305
M. Do, Sang Sun Lee, P. Jung
한국에서의 유방암 발생은 꾸준히 증가하는 추세로, 2000년도 보건복지부 통계에 의하면 여성암 중 유방암은 위암 다음으로 2위의 발생률을 나타내어 여성 암중 15.3% 를 차지하고 있다.(1) 한국 여성 유방암의 큰 특징 중의 하 나인 30∼40대 폐경 전 여성 환자의 발생률 증가(2)에 따라 암 수술 후의 젊은 환자 또한 증가하고 있다. 이렇게 지속 적으로 증가하고 있는 암 환자에 비해 암 환자의 수술, 치 료 후의 지속적인 건강 관리를 위한 기본적인 연구인 환 자의 영양 상태와 식습관 등에 대한 연구가 부족한 상황 이다. 역학적 연구 외에 암 환자에 대한 연구들을 살펴보면, 환자의 삶의 질 향상을 위한 연구의 일부로서 사회적 지 지 및 심리적인 부담에 대한 연구,(3-6) 암 환자의 간호(7) 와 영양 상태에 대한 연구들(8,9)이 있다. 하지만, 대부분 의 영양 상태에 관련된 연구들은 소화기계암인 위암과 대 장암 및 간암 등에 국한되어 있으며, 이 중 일부 연구들은 입원한 환자들의 영양 상태에 대해 보고하고 있다.(8-10) 하지만, 암의 경우 입원 당시 영양 상태도 중요하지만, 퇴원 후의 지속적인 영양 관리가 더욱 중요하다. 암 환자 에게 있어서 영양 불량 상태는 암의 치료를 방해하며, 사 망률을 증가시키는 원인이 될 수 있다.(11) 또한 암 환자 의 치료에 있어서 좋은 영양 상태의 유지 역시 중요한 치 료의 한 부분으로 인식되고 있다.(12) 암 환자의 75%는 식 욕부진과 비정상적인 대사 항진으로 열량 섭취의 감소와 더불어 에너지 요구의 증가가 일어나며, 조직의 소모 및 유방암 수술 환자의 식습관과 암 관련 정보원 이용
{"title":"Dietary Habit and Cancer Related Information Use in Postoperative Breast Cancer Patients","authors":"M. Do, Sang Sun Lee, P. Jung","doi":"10.4048/JKBCS.2002.5.4.305","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.305","url":null,"abstract":"한국에서의 유방암 발생은 꾸준히 증가하는 추세로, 2000년도 보건복지부 통계에 의하면 여성암 중 유방암은 위암 다음으로 2위의 발생률을 나타내어 여성 암중 15.3% 를 차지하고 있다.(1) 한국 여성 유방암의 큰 특징 중의 하 나인 30∼40대 폐경 전 여성 환자의 발생률 증가(2)에 따라 암 수술 후의 젊은 환자 또한 증가하고 있다. 이렇게 지속 적으로 증가하고 있는 암 환자에 비해 암 환자의 수술, 치 료 후의 지속적인 건강 관리를 위한 기본적인 연구인 환 자의 영양 상태와 식습관 등에 대한 연구가 부족한 상황 이다. 역학적 연구 외에 암 환자에 대한 연구들을 살펴보면, 환자의 삶의 질 향상을 위한 연구의 일부로서 사회적 지 지 및 심리적인 부담에 대한 연구,(3-6) 암 환자의 간호(7) 와 영양 상태에 대한 연구들(8,9)이 있다. 하지만, 대부분 의 영양 상태에 관련된 연구들은 소화기계암인 위암과 대 장암 및 간암 등에 국한되어 있으며, 이 중 일부 연구들은 입원한 환자들의 영양 상태에 대해 보고하고 있다.(8-10) 하지만, 암의 경우 입원 당시 영양 상태도 중요하지만, 퇴원 후의 지속적인 영양 관리가 더욱 중요하다. 암 환자 에게 있어서 영양 불량 상태는 암의 치료를 방해하며, 사 망률을 증가시키는 원인이 될 수 있다.(11) 또한 암 환자 의 치료에 있어서 좋은 영양 상태의 유지 역시 중요한 치 료의 한 부분으로 인식되고 있다.(12) 암 환자의 75%는 식 욕부진과 비정상적인 대사 항진으로 열량 섭취의 감소와 더불어 에너지 요구의 증가가 일어나며, 조직의 소모 및 유방암 수술 환자의 식습관과 암 관련 정보원 이용","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117285899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.298
H. Kang, S. Hong, H. Yoon, S. Ahn
유방암으로 진단을 받은 환자에 대하여 정확한 병기를 결정하는 것은 환자의 수술 후 적절한 치료방침을 결정하 는데 매우 중요하다. 최근 10년간 유방암 환자에 대한 치 료 방침은 주목할 만한 변화가 있었으며, 좀 더 많은 환자 들이 보조 항암요법 치료를 받고 있다. 수술 후 보조치료 를 하게 되는 기준으로서 종양의 크기, 액와림프절 전이 상태, 조직 등급 및 종양표지자 등의 예후인자가 쓰이고 있지만 유방암은 다양한 군으로 이루어져 있기 때문에 어 떤 환자들이 조기에 재발을 하는 지에 대한 좀더 정확한 기준이 필요하다. 유방암은 각 개개의 세포에서 다단계의 유전적인 변이를 거치면서 발생하게 되며, 전이는 신생혈 관 형성 등을 포함한 능동적인 다단계의 과정으로서 암세 포의 주변 간질조직, 림프관, 혈관으로의 국소 침윤, 순환 혈류로의 침투 및 다른 장기로의 이동 등의 과정이 포함 된다.(1) 종양의 크기가 작아도 암세포의 확산이 발견될 수 있고, 수술로 원발 종양을 제거한 후에도 림프계나 순 환 혈류에 암세포가 잔존할 수 있어 보편적인 방법으로는 발견할 수 없는 이들 암세포가 유방암 재발의 원인이라고 생각한다.(2) 이러한 이유로 유방암 환자의 말초혈액에 존 재하는 유방암 세포를 발견하는 것이 환자의 생존을 예측 하는 중요한 예후인자로 부각되고 있으며 이에 따라 보조 치료의 방법을 선택하는 기준과 일차 치료 후 추적조사의 유용한 방법이 될 것으로 생각한다.(3,4) 그러나 혈액표본 에 대한 직접적인 세포검사는 진단적 예민도가 매우 낮으 책임저자:안세현, 서울시 송파구 풍납 2동 388-1 ꂕ 138-736, 울산대학교 의과대학 외과학교실 Tel: 02-3010-3490, Fax: 02-474-9027 E-mail: ahnsh@amc.seoul.kr 접수일:2002년 11월 5일, 게재승인일:2002년 12월 15일 유방암 환자의 말초혈액에서 RT-PCR을 이용한 미세전이의 발견: MUC1, CK19, hMMG의 결과 비교
{"title":"Detection of Micrometastasis in Peripheral Blood of Breast Cancer Patients Using RT-PCR Assay: Comparison of MUC1, CK19 and hMMG","authors":"H. Kang, S. Hong, H. Yoon, S. Ahn","doi":"10.4048/JKBCS.2002.5.4.298","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.298","url":null,"abstract":"유방암으로 진단을 받은 환자에 대하여 정확한 병기를 결정하는 것은 환자의 수술 후 적절한 치료방침을 결정하 는데 매우 중요하다. 최근 10년간 유방암 환자에 대한 치 료 방침은 주목할 만한 변화가 있었으며, 좀 더 많은 환자 들이 보조 항암요법 치료를 받고 있다. 수술 후 보조치료 를 하게 되는 기준으로서 종양의 크기, 액와림프절 전이 상태, 조직 등급 및 종양표지자 등의 예후인자가 쓰이고 있지만 유방암은 다양한 군으로 이루어져 있기 때문에 어 떤 환자들이 조기에 재발을 하는 지에 대한 좀더 정확한 기준이 필요하다. 유방암은 각 개개의 세포에서 다단계의 유전적인 변이를 거치면서 발생하게 되며, 전이는 신생혈 관 형성 등을 포함한 능동적인 다단계의 과정으로서 암세 포의 주변 간질조직, 림프관, 혈관으로의 국소 침윤, 순환 혈류로의 침투 및 다른 장기로의 이동 등의 과정이 포함 된다.(1) 종양의 크기가 작아도 암세포의 확산이 발견될 수 있고, 수술로 원발 종양을 제거한 후에도 림프계나 순 환 혈류에 암세포가 잔존할 수 있어 보편적인 방법으로는 발견할 수 없는 이들 암세포가 유방암 재발의 원인이라고 생각한다.(2) 이러한 이유로 유방암 환자의 말초혈액에 존 재하는 유방암 세포를 발견하는 것이 환자의 생존을 예측 하는 중요한 예후인자로 부각되고 있으며 이에 따라 보조 치료의 방법을 선택하는 기준과 일차 치료 후 추적조사의 유용한 방법이 될 것으로 생각한다.(3,4) 그러나 혈액표본 에 대한 직접적인 세포검사는 진단적 예민도가 매우 낮으 책임저자:안세현, 서울시 송파구 풍납 2동 388-1 ꂕ 138-736, 울산대학교 의과대학 외과학교실 Tel: 02-3010-3490, Fax: 02-474-9027 E-mail: ahnsh@amc.seoul.kr 접수일:2002년 11월 5일, 게재승인일:2002년 12월 15일 유방암 환자의 말초혈액에서 RT-PCR을 이용한 미세전이의 발견: MUC1, CK19, hMMG의 결과 비교","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133891404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.323
Woo-Shin Shim
Breast cancer is now the second most cancer in women after stomach cancer in Korea, and is increasing continuously. In the year 2000, the crude incidence of breast cancer in Korea was estimated about 23 per 100,000 people.(1) For the process of inducing breast cancer, estrogens appear to play a predominant role. These sex steroids are believed to initiate and to promote the process of the breast carcinogenesis by enhancing the rate of cell division and reducing time available for DNA repair. A new concept is that estrogens can be metabolized to catechol-estrogens and then to quinines that directly damage DNA. These two process-estrogen receptor mediated, genomic effects on proliferation and receptor independent, genotoxic effects of estrogen metabolites-can act in an additive or synergistic fashion to cause breast cancer.(2) Breast cancers that arise in patients can be divided into hormone dependent and hormone independent subtypes.(3) The role of estrogens as modulators of mitogenesis override the influence of other factors in the hormone dependent subtype. These sex steroids stimulate cell proliferation directly by increasing the rate of transcription of early response genes such as c-myc and indirectly through stimulation of growth factors which are produced largely in response to estrogenic regulation.(4) Based upon the concept that estrogen is the proximate regulator of cell proliferation, two general strategies were developed for treatment of hormone dependent breast cancer: blockade of estrogen receptor (ER) action and inhibition of estradiol biosynthesis. Antiestrogens such as tamoxifen bind to ER and interfere with transcription of estrogen induced genes involved in regulating cell proliferation. Clinical trials showed tamoxifen to be effective in inducing objective tumor regressions and to be associated with minimal side effects and toxicity. The second strategy, blockade of estradiol biosynthesis, was demonstrated to be feasible using the steroidogenesis inhibitor, aminoglutethimide, which produced tumor regressions equivalent to those observed with tamoxifen.(3) However, side effects from aminoglutethimide were considerable and its effects on several steroidogenic enzymes required concomitant use of a glucocorticoid. Consequently, tamoxifen became the preferred, first line endocrine agent with which to treat ER-positive advanced breast cancer. However, the clinical efficacy of aminoglutethimide focused attention upon the need to develop more potent, better tolerated, and more specific inhibitors of estrogen biosynthesis.
{"title":"Aromtase Inhibitors in Breast Cancer","authors":"Woo-Shin Shim","doi":"10.4048/JKBCS.2002.5.4.323","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.323","url":null,"abstract":"Breast cancer is now the second most cancer in women after stomach cancer in Korea, and is increasing continuously. In the year 2000, the crude incidence of breast cancer in Korea was estimated about 23 per 100,000 people.(1) For the process of inducing breast cancer, estrogens appear to play a predominant role. These sex steroids are believed to initiate and to promote the process of the breast carcinogenesis by enhancing the rate of cell division and reducing time available for DNA repair. A new concept is that estrogens can be metabolized to catechol-estrogens and then to quinines that directly damage DNA. These two process-estrogen receptor mediated, genomic effects on proliferation and receptor independent, genotoxic effects of estrogen metabolites-can act in an additive or synergistic fashion to cause breast cancer.(2) Breast cancers that arise in patients can be divided into hormone dependent and hormone independent subtypes.(3) The role of estrogens as modulators of mitogenesis override the influence of other factors in the hormone dependent subtype. These sex steroids stimulate cell proliferation directly by increasing the rate of transcription of early response genes such as c-myc and indirectly through stimulation of growth factors which are produced largely in response to estrogenic regulation.(4) Based upon the concept that estrogen is the proximate regulator of cell proliferation, two general strategies were developed for treatment of hormone dependent breast cancer: blockade of estrogen receptor (ER) action and inhibition of estradiol biosynthesis. Antiestrogens such as tamoxifen bind to ER and interfere with transcription of estrogen induced genes involved in regulating cell proliferation. Clinical trials showed tamoxifen to be effective in inducing objective tumor regressions and to be associated with minimal side effects and toxicity. The second strategy, blockade of estradiol biosynthesis, was demonstrated to be feasible using the steroidogenesis inhibitor, aminoglutethimide, which produced tumor regressions equivalent to those observed with tamoxifen.(3) However, side effects from aminoglutethimide were considerable and its effects on several steroidogenic enzymes required concomitant use of a glucocorticoid. Consequently, tamoxifen became the preferred, first line endocrine agent with which to treat ER-positive advanced breast cancer. However, the clinical efficacy of aminoglutethimide focused attention upon the need to develop more potent, better tolerated, and more specific inhibitors of estrogen biosynthesis.","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116719881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.273
Sung Hwan Park, D. Choi, Kihyuk Park, D. Joo, H. Lee, Y. Yoo, K. Park, In Soo Suh
암 연구에서 인체 실험은 가장 이상적인 결과를 얻을 수 있는 수단이다. 그러나 인체 실험은 적지 않은 윤리적 및 기술적인 어려움으로 인하여 극히 제한적으로만 가능 할 뿐이다. 따라서 인체 내의 여러가지 조건들과 유사한 환경을 제공할 수 있는 우수한 동물 모델의 개발은 인체 실험에서 나타날 수 있는 위험을 줄이고, 암 발생의 생물 학적인 과정을 밝히며, 새로운 치료법의 개발에 따른 노 력과 비용을 최소화시킬 수 있는 꼭 필요한 방법이다. 그 중에서도 쥐 모델은 암 연구에서 대체하기 어려울 만큼 광범위하게 사용되고 있다. 특히 1962년 흉선이 없는 nude mouse에서 활성화된 T-림프구의 결핍으로 인한 면역 거부 반응의 약화가 알려진 후, nude mouse에 인간의 암 세포나 조직을 이식한 암 연구가 활기를 띠게 되었다. 또한 최근 severe combined immunodeficient (SCID) mouse와 transgenic mouse가 실험에 사용되기 시작한 후에는 한층 더 인체에 가까운 조건에서 쥐 모델을 이용한 세밀하고 구체적인 암 연구가 가능해졌다. SCID mouse는 1983년 Bosma 등(1)이 처음 발견하여 보고하였는데, 이는 생쥐 16번 염색체의 SCID locus에 위치하는 두 대립유전자(allele)들이 유전자 돌연변이 때문에 비활성화되면서 해당 DNA 복구효소 (repair enzyme)의 생성 결핍이 나타나고, 그로 인한 B 및 T 림프구 분화 과정의 V-D-J 유전자(gene)들의 재조합 장 애 때문에 초래된 것이다.(2-4) 따라서 SCID mouse의 림프 구들은 면역 활성이 없는 pro-B cell 및 미숙가슴샘세포 (immature thymocyte) 상태로 남게 되며, 성숙한 B 및 T 림 프구가 결핍된 SCID mouse는 동종은 물론 이종 조직 이 식에도 비교적 약한 거부 반응을 나타나기 때문에 암을 비롯한 선천성 및 후천성 면역결핍증, 감염, 장기 이식 및 human cancers including breast cancer. (Journal of Korean Breast Cancer Society 2002;5:273-278) ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
在癌症研究中,人体实验是获得最理想结果的手段。但是,由于不少伦理和技术上的困难,人体实验只能在极有限的范围内进行。因此,人体内的各种条件和类似的环境可以提供优秀的动物模型的开发,在人体试验中可能出现的风险,减少癌症发生的生物科学过程表明,开发新的治疗方法带来的卢历史和费用至少也使必要的方法。其中,老鼠模型在癌症研究中被广泛使用,难以替代。1962年,随着T-淋巴球在无胸腺的nude mouse中活性化,免疫排斥反应减弱的消息被公开,将人类癌细胞或组织移植到nude mouse的癌症研究变得活跃起来。另外,severe combined immunodeficient (SCID) mouse和transgenic mouse最近开始被用于实验后,在更接近人体的条件下,可以利用老鼠模型进行细致而具体的癌症研究。1983年,Bosma等人(1)首次发现并报告了SCID mouse,这是因为位于第16对老鼠染色体SCID locus的两个对立基因(allele)因基因突变而失效,导致DNA修复酶(repair enzyme)缺乏生成。B和T淋巴球分化过程中的V-D-J基因重组障碍(2-4)因此,SCID mouse的淋巴球仍处于没有免疫活性的pro-B cell和未成熟的胸腺细胞(immature thymocyte)状态。缺乏成熟的B和T淋巴结的SCID mouse不仅对同种组织,而且对异种组织的移植也表现出较弱的排斥反应,因此,包括癌症在内的先天性及后天性免疫缺乏症、感染、脏器移植及human cancers including breast cancer。(journal of korean breast cancer society 2002; 5: 273 - 278)ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
{"title":"Growth and Metastasis of MCF-7 Breast Cancer Cells Grafted to huPBMC-SCID Mouse","authors":"Sung Hwan Park, D. Choi, Kihyuk Park, D. Joo, H. Lee, Y. Yoo, K. Park, In Soo Suh","doi":"10.4048/JKBCS.2002.5.4.273","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.273","url":null,"abstract":"암 연구에서 인체 실험은 가장 이상적인 결과를 얻을 수 있는 수단이다. 그러나 인체 실험은 적지 않은 윤리적 및 기술적인 어려움으로 인하여 극히 제한적으로만 가능 할 뿐이다. 따라서 인체 내의 여러가지 조건들과 유사한 환경을 제공할 수 있는 우수한 동물 모델의 개발은 인체 실험에서 나타날 수 있는 위험을 줄이고, 암 발생의 생물 학적인 과정을 밝히며, 새로운 치료법의 개발에 따른 노 력과 비용을 최소화시킬 수 있는 꼭 필요한 방법이다. 그 중에서도 쥐 모델은 암 연구에서 대체하기 어려울 만큼 광범위하게 사용되고 있다. 특히 1962년 흉선이 없는 nude mouse에서 활성화된 T-림프구의 결핍으로 인한 면역 거부 반응의 약화가 알려진 후, nude mouse에 인간의 암 세포나 조직을 이식한 암 연구가 활기를 띠게 되었다. 또한 최근 severe combined immunodeficient (SCID) mouse와 transgenic mouse가 실험에 사용되기 시작한 후에는 한층 더 인체에 가까운 조건에서 쥐 모델을 이용한 세밀하고 구체적인 암 연구가 가능해졌다. SCID mouse는 1983년 Bosma 등(1)이 처음 발견하여 보고하였는데, 이는 생쥐 16번 염색체의 SCID locus에 위치하는 두 대립유전자(allele)들이 유전자 돌연변이 때문에 비활성화되면서 해당 DNA 복구효소 (repair enzyme)의 생성 결핍이 나타나고, 그로 인한 B 및 T 림프구 분화 과정의 V-D-J 유전자(gene)들의 재조합 장 애 때문에 초래된 것이다.(2-4) 따라서 SCID mouse의 림프 구들은 면역 활성이 없는 pro-B cell 및 미숙가슴샘세포 (immature thymocyte) 상태로 남게 되며, 성숙한 B 및 T 림 프구가 결핍된 SCID mouse는 동종은 물론 이종 조직 이 식에도 비교적 약한 거부 반응을 나타나기 때문에 암을 비롯한 선천성 및 후천성 면역결핍증, 감염, 장기 이식 및 human cancers including breast cancer. (Journal of Korean Breast Cancer Society 2002;5:273-278) ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115857400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.319
W. Park, K. Sung, Jeong soo Kim, S. Oh, S. Choi, Y. You, H. M. Chun, I. Kim, S. Jung
80.59%, 85.71% (Log rank test, P=0.22) in receptor (+) and (-) group, respectively. Conclusion: Even though the results were not statistically significant, the overall survival of receptor positive group was inferior to that of receptor negative group among the very young premenopausal women with early breast cancer. For the confirmation of the results and better treatment for very young women, a large, prospective case-control study is needed. (Journal of Korean Breast Cancer Society 2002; 5:319-322) ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
{"title":"Prognostic Significance of Hormonal Receptors in Very Young Women with Early Breast Cancer","authors":"W. Park, K. Sung, Jeong soo Kim, S. Oh, S. Choi, Y. You, H. M. Chun, I. Kim, S. Jung","doi":"10.4048/JKBCS.2002.5.4.319","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.319","url":null,"abstract":"80.59%, 85.71% (Log rank test, P=0.22) in receptor (+) and (-) group, respectively. Conclusion: Even though the results were not statistically significant, the overall survival of receptor positive group was inferior to that of receptor negative group among the very young premenopausal women with early breast cancer. For the confirmation of the results and better treatment for very young women, a large, prospective case-control study is needed. (Journal of Korean Breast Cancer Society 2002; 5:319-322) ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132323387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.279
Tae-Soon Lee, Sung Hwan Park, Jong Won Lee, S. Lim
Purpose: In solid tumor, there is a region where oxygen supply is insufficient. Under this hypoxic condition, cancer cells became more resistant than normal cells. In this study, we found that one of the aminoglycoside antibiotics, geneticin, made a human breast cancer cell, MCF-7, even more resistant to hypoxia. Methods: On normoxic (21% O2) condition, MCF-7 cells (1.5 ×10 cells/60 mm culture dish) were grown in low glucose (1 g/l) MEM (with 10% FBS) supplemented with 0, 1, 10, 100, and 1000μg/dl geneticin, respectively, for one day. Then, the cells were transferred to hypoxic (1% O2) incubator and grown for 3 days. We examined the viability of cells, the concentration of glucose and lactate and DNA fragmentation assay in each groups. Results: When the cells were grown in low glucose medium under hypoxia (1% O2), all the cells became dead after 2 days of culture in the absence of geneticin whereas the cells still survived even after 3 days of culture in the presence of geneticin (10μg/ml). In the presence of geneticin, the cells survived despite of consumption of all glucose in the medium, whereas the cells became dead once all glucose was consumed in the absence of geneticin. In this case, 저산소 조건에서 제네티신이 유방암세포의 생존에 미치는 영향
{"title":"The Effect of Geneticin on the Survival of a Human Breast Cancer Cells under Hypoxic Condition","authors":"Tae-Soon Lee, Sung Hwan Park, Jong Won Lee, S. Lim","doi":"10.4048/JKBCS.2002.5.4.279","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.279","url":null,"abstract":"Purpose: In solid tumor, there is a region where oxygen supply is insufficient. Under this hypoxic condition, cancer cells became more resistant than normal cells. In this study, we found that one of the aminoglycoside antibiotics, geneticin, made a human breast cancer cell, MCF-7, even more resistant to hypoxia. Methods: On normoxic (21% O2) condition, MCF-7 cells (1.5 ×10 cells/60 mm culture dish) were grown in low glucose (1 g/l) MEM (with 10% FBS) supplemented with 0, 1, 10, 100, and 1000μg/dl geneticin, respectively, for one day. Then, the cells were transferred to hypoxic (1% O2) incubator and grown for 3 days. We examined the viability of cells, the concentration of glucose and lactate and DNA fragmentation assay in each groups. Results: When the cells were grown in low glucose medium under hypoxia (1% O2), all the cells became dead after 2 days of culture in the absence of geneticin whereas the cells still survived even after 3 days of culture in the presence of geneticin (10μg/ml). In the presence of geneticin, the cells survived despite of consumption of all glucose in the medium, whereas the cells became dead once all glucose was consumed in the absence of geneticin. In this case, 저산소 조건에서 제네티신이 유방암세포의 생존에 미치는 영향","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114345276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.291
C. Kim, K. Yang, Byung-Noe Bae, Ki Hwan Kim, Hongyong Kim, Young Duck Kim, H. Kim, Kyeongmee Park, Sehwan Han
{"title":"Significance of the Expression of p27Kip1 Protein in Human Breast Cancer","authors":"C. Kim, K. Yang, Byung-Noe Bae, Ki Hwan Kim, Hongyong Kim, Young Duck Kim, H. Kim, Kyeongmee Park, Sehwan Han","doi":"10.4048/JKBCS.2002.5.4.291","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.291","url":null,"abstract":"","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121237160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.311
S. Ko, Ilhak Lee, Seung-Ki Kim, Seung-Il Kim, Byeong-Woo Park, Kyong-Sik Lee
후 국소진행성 유방암에서 유도화학요법의 효용성이 여 IIIB, and 16 (13.1%) in IIIC at diagnosis. 10 patients (8.2%) have shown CR, 85 (69.7%) patients PR, and the remaining 27 (22.1%) patients showed NR. The overall response rate to neoadjuvant chemotherapy was 77.5%. However, only 51 (41.8%) were demonstrated to have pathologically downstaged results. There were 32 loco-regional recurrences and 59 distant metastases. All of the initial clinical stage, clinical response to neoadjuvant chemotherapy, and pathologic stage influenced the final outcome of 10 year OS, LRRFS, DRFS. However, in multivariate analysis pathologic stage after neoadjuvant chemotherapy was the most influencing factor on the final outcome. Conclusion: Pathologic stage after neoadjuvant chemotherapy could be the most important prognostic factor of the LABC. (Journal of Korean Breast Cancer Society 2002; 5:311-318)
{"title":"Neoadjuvant Chemotherapy for the Local Advanced Breast Cancer","authors":"S. Ko, Ilhak Lee, Seung-Ki Kim, Seung-Il Kim, Byeong-Woo Park, Kyong-Sik Lee","doi":"10.4048/JKBCS.2002.5.4.311","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.311","url":null,"abstract":"후 국소진행성 유방암에서 유도화학요법의 효용성이 여 IIIB, and 16 (13.1%) in IIIC at diagnosis. 10 patients (8.2%) have shown CR, 85 (69.7%) patients PR, and the remaining 27 (22.1%) patients showed NR. The overall response rate to neoadjuvant chemotherapy was 77.5%. However, only 51 (41.8%) were demonstrated to have pathologically downstaged results. There were 32 loco-regional recurrences and 59 distant metastases. All of the initial clinical stage, clinical response to neoadjuvant chemotherapy, and pathologic stage influenced the final outcome of 10 year OS, LRRFS, DRFS. However, in multivariate analysis pathologic stage after neoadjuvant chemotherapy was the most influencing factor on the final outcome. Conclusion: Pathologic stage after neoadjuvant chemotherapy could be the most important prognostic factor of the LABC. (Journal of Korean Breast Cancer Society 2002; 5:311-318)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115928925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-12-01DOI: 10.4048/JKBCS.2002.5.4.284
W. Han, K. Chung, Soo‐Jung Ahn, D. Noh, Y. Youn, S. Oh, K. Choe
Purpose: Breast cancer is characterized by an extensive heterogeneity that complicates the precise assessment of tumor aggressiveness and makes therapeutic decisions difficult. Variation in transcriptional programs accounts for much of the biological diversity of the tumors. We tried to investigate the gene expression profile of Korean breast cancer with cDNA microarray technique. Methods: We have characterized variation in gene expression patterns in 7 tissue samples of infiltrating ductal carcinoma from different individuals and 1 tissue sample of malignant phyllodes tumor using cDNA microarray representing 7,500 human genes. Breast cancer cell line, MCF7 and T lymphoblastoid cell line, CCRF-CEM were also included in this study. RNA extracted from normal breast tissue of 3 non-cancer individuals were pooled and used as a control sample. We analyzed the data with Cluster and TreeView program. Results: Tissues from infiltrating ductal carcinoma and tissue from phyllodes tumor and 2 cell lines are clearly differentiated by hierarchical clustering as their pathologic features and showed characteristic genetic expression. Some interesting clusters were found. They were 'stromal cluster', 'immune cluster', 'proliferation and transcription cluster', and a cluster including FOS and JUNB gene. Phylldes tumor showed distinctive genetic expression pattern compared with ductal carcinoma tissues. Two patients whose c-erbB2 protein had been measured as highest level in immunohistochemistry showed overexpression of ERBB2 gene. GRB7, MLN51, and PPARBP in 17q21 that are known to coexpress with ERBB2 also showed overexpression in these patients. Conclusion: We found some interesting clusters and confirmed the feasibility of cDNA microarray in the study of breast cancer. This preliminary study will help the further research of DNA microarray with lager sample size. (Journal of Korean Breast Cancer Society 2002;5:284-290)
{"title":"Gene Expression Profiles of Primary Breast Cancer Tissue Using cDNA Microarray","authors":"W. Han, K. Chung, Soo‐Jung Ahn, D. Noh, Y. Youn, S. Oh, K. Choe","doi":"10.4048/JKBCS.2002.5.4.284","DOIUrl":"https://doi.org/10.4048/JKBCS.2002.5.4.284","url":null,"abstract":"Purpose: Breast cancer is characterized by an extensive heterogeneity that complicates the precise assessment of tumor aggressiveness and makes therapeutic decisions difficult. Variation in transcriptional programs accounts for much of the biological diversity of the tumors. We tried to investigate the gene expression profile of Korean breast cancer with cDNA microarray technique. Methods: We have characterized variation in gene expression patterns in 7 tissue samples of infiltrating ductal carcinoma from different individuals and 1 tissue sample of malignant phyllodes tumor using cDNA microarray representing 7,500 human genes. Breast cancer cell line, MCF7 and T lymphoblastoid cell line, CCRF-CEM were also included in this study. RNA extracted from normal breast tissue of 3 non-cancer individuals were pooled and used as a control sample. We analyzed the data with Cluster and TreeView program. Results: Tissues from infiltrating ductal carcinoma and tissue from phyllodes tumor and 2 cell lines are clearly differentiated by hierarchical clustering as their pathologic features and showed characteristic genetic expression. Some interesting clusters were found. They were 'stromal cluster', 'immune cluster', 'proliferation and transcription cluster', and a cluster including FOS and JUNB gene. Phylldes tumor showed distinctive genetic expression pattern compared with ductal carcinoma tissues. Two patients whose c-erbB2 protein had been measured as highest level in immunohistochemistry showed overexpression of ERBB2 gene. GRB7, MLN51, and PPARBP in 17q21 that are known to coexpress with ERBB2 also showed overexpression in these patients. Conclusion: We found some interesting clusters and confirmed the feasibility of cDNA microarray in the study of breast cancer. This preliminary study will help the further research of DNA microarray with lager sample size. (Journal of Korean Breast Cancer Society 2002;5:284-290)","PeriodicalId":414717,"journal":{"name":"Journal of Korean Breast Cancer Society","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2002-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121904321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}